Elliot Goldstein
Nessuna posizione attualmente
Storia della carriera di Elliot Goldstein
Precedenti posizioni note di Elliot Goldstein
Società | Posizione | Inizio | Fine |
---|---|---|---|
PROMIS NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | 29/09/2014 | 22/10/2021 |
Amministratore Delegato | 01/07/2015 | 22/10/2021 | |
Presidente | 01/07/2015 | 22/10/2021 | |
IMMUNE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 02/04/2014 | 01/12/2014 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Direttore operativo | 01/02/2003 | 30/10/2009 |
Direttore Tecnico/Scientifico/R&S | 01/02/2003 | 30/10/2009 | |
VERNALIS | Amministratore Delegato | 01/09/1998 | 01/11/2002 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - | - |
Virtua LLC | Fondatore | 01/01/2014 | - |
Sandoz Pharmaceuticals Corp. | Direttore Tecnico/Scientifico/R&S | - | - |
Sandoz Research Institute | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Elliot Goldstein
McGill University | Undergraduate Degree |
Université d'Aix-Marseille | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Canada | 4 |
Regno Unito | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 4 |
Chief Executive Officer | 2 |
Chief Operating Officer | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
PROMIS NEUROSCIENCES, INC. | Health Technology |
Aziende private | 7 |
---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Sandoz Research Institute | |
Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Sandoz Pharmaceuticals Corp. | |
Virtua LLC | |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
- Borsa valori
- Insiders
- Elliot Goldstein
- Esperienza